The Journal of Nuclear Medicine最新文献

{"title":"Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic 18F-FDG PET Kinetic Modeling","authors":"Kevin J. Chung, Abhijit J. Chaudhari, Lorenzo Nardo, Terry Jones, Moon S. Chen, Ramsey D. Badawi, Simon R. Cherry, Guobao Wang","doi":"10.2967/jnumed.124.268706","DOIUrl":"https://doi.org/10.2967/jnumed.124.268706","url":null,"abstract":"<p>Past efforts to measure blood flow with the widely available radiotracer ¹⁸F-FDG were limited to tissues with high ¹⁸F-FDG extraction fraction. In this study, we developed an early dynamic ¹⁸F-FDG PET method with high-temporal-resolution (HTR) kinetic modeling to assess total-body blood flow based on deriving the vascular phase of ¹⁸F-FDG transit and conducted a pilot comparison study against a ¹¹C-butanol flow-tracer reference. <b>Methods:</b> The first 2 min of dynamic PET scans were reconstructed at HTR (60 <FONT FACE=\"arial,helvetica\">x</FONT> 1 s/frame, 30 <FONT FACE=\"arial,helvetica\">x</FONT> 2 s/frame) to resolve the rapid passage of the radiotracer through blood vessels. In contrast to existing methods that use blood-to-tissue transport rate as a surrogate of blood flow, our method directly estimated blood flow using a distributed kinetic model (adiabatic approximation to tissue homogeneity [AATH] model). To validate our ¹⁸F-FDG measurements of blood flow against a reference flow-specific radiotracer, we analyzed total-body dynamic PET images of 6 human participants scanned with both ¹⁸F-FDG and ¹¹C-butanol. An additional 34 total-body dynamic ¹⁸F-FDG PET images of healthy participants were analyzed for comparison against published blood-flow ranges. Regional blood flow was estimated across the body, and total-body parametric imaging of blood flow was conducted for visual assessment. AATH and standard compartment model fitting was compared using the Akaike information criterion at different temporal resolutions. <b>Results:</b> ¹⁸F-FDG blood flow was in quantitative agreement with flow measured from ¹¹C-butanol across same-subject regional measurements (Pearson correlation coefficient, 0.955; <I>P</I> &lt; 0.001; linear regression slope and intercept, 0.973 and &ndash;0.012, respectively), which was visually corroborated by total-body blood-flow parametric imaging. Our method resolved a wide range of blood-flow values across the body in broad agreement with published ranges (e.g., healthy cohort values of 0.51 &plusmn; 0.12 mL/min/cm³ in the cerebral cortex and 2.03 &plusmn; 0.64 mL/min/cm³ in the lungs). HTR (1&ndash;2 s/frame) was required for AATH modeling. <b>Conclusion:</b> Total-body blood-flow imaging was feasible using early dynamic ¹⁸F-FDG PET with HTR kinetic modeling. This method may be combined with standard ¹⁸F-FDG PET methods to enable efficient single-tracer multiparametric flow-metabolism imaging, with numerous research and clinical applications in oncology, cardiovascular disease, pain medicine, and neuroscience.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration","authors":"Romy Cools, Koen Vermeulen, Eline Vonck, Veerle Baekelandt, Cassis Varlow, Valeria Narykina, Christopher Cawthorne, Koen Van Laere, Wim Vanduffel, Neil Vasdev, Guy Bormans","doi":"10.2967/jnumed.124.268961","DOIUrl":"https://doi.org/10.2967/jnumed.124.268961","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268961absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"90 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approaches to Imaging Immune Activation Using PET","authors":"Ashwin Singh Parihar, Niharika Pant, Pedram Heidari, Lawrence Fong, Amir Iravani","doi":"10.2967/jnumed.124.268289","DOIUrl":"https://doi.org/10.2967/jnumed.124.268289","url":null,"abstract":"<p>This review explores the role of PET in imaging immune activation, particularly in oncology. ¹⁸F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique response patterns as well as immune-related adverse events. However, because of the limited specificity of ¹⁸F-FDG, newer PET radiopharmaceuticals targeting specific cellular or subcellular components of the immune system have been developed that can provide more precise information. The development of immune-specific PET radiopharmaceuticals offers significant potential for improving immune monitoring in both clinical practice and research.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol","authors":"Sara Harsini, Maryam Soleimani, Don Wilson, Carlos Uribe, Heather Saprunoff, Ingrid Bloise, Francois Benard","doi":"10.2967/jnumed.124.269064","DOIUrl":"https://doi.org/10.2967/jnumed.124.269064","url":null,"abstract":"<p>Prostate-specific membrane antigen (PSMA)–targeting radiopharmaceuticals, such as the novel [¹⁷⁷Lu]Lu-HTK03170, present a promising therapeutic option for metastatic castration-resistant prostate cancer (mCRPC). [¹⁷⁷Lu]Lu-HTK03170, being used in humans for the first time in this trial, was specifically designed to improve tumor specificity and minimize off-target toxicity, addressing the limitations of existing PSMA radiopharmaceutical therapies. This phase I/II clinical trial aims to evaluate the safety, dosimetry, and efficacy of [¹⁷⁷Lu]Lu-HTK03170 in patients with PSMA-positive mCRPC who have progressed on androgen receptor pathway inhibitors with or without taxane chemotherapy. <strong>Methods:</strong> This first-in-human, open-label, single-center phase I/II trial is designed to assess the safety and efficacy of [¹⁷⁷Lu]Lu-HTK03170. Phase I follows a traditional 3 + 3 dose-escalation design to determine the maximum tolerated injected activity of the first injection of [¹⁷⁷Lu]Lu-HTK03170, followed by personalized dosimetry to calculate the activity of each subsequent injection. Dose-limiting toxicities will be used to guide dose adjustments, with personalized dosimetry used to monitor absorbed doses to critical organs. Up to 18 patients are expected to be enrolled in phase I. Phase II, using a Simon 2-stage design, will evaluate the treatment’s efficacy, with approximately 32 patients expected to enroll. Each participant will receive up to 7 treatment cycles administered every 8 wk. In phase I, the primary endpoints include determining the maximum tolerated injected activity and safety profile, which will be assessed by the occurrence of dose-limiting toxicities and the measurement of absorbed doses to normal organs. In phase II, the primary endpoint is the objective response rate as defined by RECIST 1.1. Secondary endpoints include prostate-specific antigen response rate, progression-free survival, overall survival, time to symptomatic skeletal events, and quality of life. Exploratory endpoints include evaluating circulating tumor DNA/RNA as potential biomarkers for treatment response. <strong>Conclusion:</strong> This ongoing first-in-human trial aims to establish the safety, dosimetry, and preliminary efficacy of [¹⁷⁷Lu]Lu-HTK03170 in patients with PSMA-positive mCRPC. The results of this study will inform the clinical development of [¹⁷⁷Lu]Lu-HTK03170 as a potential treatment option for mCRPC.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma","authors":"Alexandre França Velo, Alexandra Giantini Larsen, John L. Humm, Pat Zanzonico, Sofia Haque, Marc Souweidane, Neeta Pandit-Taskar","doi":"10.2967/jnumed.124.267995","DOIUrl":"https://doi.org/10.2967/jnumed.124.267995","url":null,"abstract":"<p>This phase 1, dose-escalation study examined the use of the radiolabeled antibody ¹²⁴I-Omburtamab delivered directly to brain-stem tumors via convection-enhanced delivery (CED). CED bypasses the blood–brain barrier by injecting the agent under the pressure of a peristaltic pump to convectively drive the therapeutic agent through the brain tissue and tumor compartment, enabling high concentrations at the target site. We evaluated ¹²⁴I-Omburtamab’s potential to deliver therapeutic radiation doses to diffuse intrinsic pontine glioma in children. PET and MRI were used to assess the alignment between the intended and actual distribution of the agent, with an analysis of tumor coverage and radiation absorbed doses. <strong>Methods:</strong> ¹²⁴I-Omburtamab doses ranging from 9.25 to 370 MBq were administered to 36 patients. Tumor distribution volumes were derived from PET images by placing volumes of interest over lesions and overlaying them onto T2-weighted fluid-attenuated inversion recovery MRI-delineated tumor volumes. Dosimetry metrics evaluated after CED included dose-volume histograms, tumor coverage percentage, and the Dice similarity coefficient between the antibody distribution and tumor volume. A 4-quadrant scatter plot of Dice similarity versus tumor coverage was used to classify treatment variations among patients. <strong>Results:</strong> Serial PET scans showed ¹²⁴I-Omburtamab localization in brain-stem lesions from 1 h to 7 d ± 1 d after dose administration. Coverage analysis revealed that 29 patients had tumor volume coverage greater than 50%, and 28 had a Dice similarity coefficient over 50%. The 4-quadrant statistical analysis—percentage of coverage versus Dice similarity coefficient—showed that 27 patients had acceptable coverage for treatment, and 4 patients experiencing suboptimal tumor coverage. <strong>Conclusion:</strong> CED of ¹²⁴I-Omburtamab is a novel approach for delivering radiolabeled therapies into brain-stem tumors. Imaging enabled quantification of radiation dose coverage within the MRI-defined tumor target, highlighting the importance of precise alignment between therapeutic agent distribution and tumor volume.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"136 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study","authors":"Binyu Shi, You Zhang, Shuo Wu, Dongsheng Xu, Qianyun Wu, Wenzhi Jia, Shuxian An, Cheng Wang, Yongrui Bai, Jianjun Liu, Junjun Zhou, Weijun Wei","doi":"10.2967/jnumed.125.269585","DOIUrl":"https://doi.org/10.2967/jnumed.125.269585","url":null,"abstract":"<p>CD70 has emerged as a promising biomarker for nasopharyngeal carcinoma (NPC). This study investigated CD70 expression patterns in NPC specimens and evaluated the diagnostic potential of CD70-targeted [¹⁸F]RCCB6 immuno-PET/CT in patients with NPC. <strong>Methods:</strong> CD70 expression was analyzed in 80 archived NPC specimens and correlated with clinical and pathologic features. Using [¹⁸F]RCCB6, a single-domain antibody–derived tracer specific for human CD70, the diagnostic efficacy of [¹⁸F]RCCB6 immuno-PET/CT was assessed in 25 patients with NPC and compared with that of ¹⁸F-FDG PET/CT. <strong>Results:</strong> CD70 was positively expressed in 72 (90%) of 80 NPC specimens, with expression levels strongly correlated with Epstein-Barr virus (EBV) titers (r_s = 0.437; <em>P</em> &lt; 0.001) and N-staging (<em>P</em> = 0.006). In all 15 patients with early-stage NPC, [¹⁸F]RCCB6 immuno-PET/CT achieved a 100% detection rate of the primary tumor and a 93% detection rate (75/81) of local lymph node metastasis. [¹⁸F]RCCB6 uptake correlated well with CD70 expression. In a head-to-head comparison, [¹⁸F]RCCB6 demonstrated higher sensitivity than did ¹⁸F-FDG in detecting lymph node metastasis (100% [58/58] vs. 90% [52/58], respectively; <em>P</em> = 0.031), and equivalent detection abilities for primary lesions and most distant metastases (100%). Notably, [¹⁸F]RCCB6 immuno-PET/CT demonstrated better evaluation of skull-base invasion with a clear border and bone metastases, as indicated by its higher uptake compared with ¹⁸F-FDG (7.25 vs. 5.95; <em>P</em> = 0.025). <strong>Conclusion:</strong> CD70 is a potent biomarker for NPC. [¹⁸F]RCCB6 immuno-PET/CT provides precise mapping of CD70 expression and enhances the diagnosis of primary, metastatic, and recurrent NPCs, outperforming ¹⁸F-FDG in detecting skull-base invasion and metastases.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System","authors":"Charlotte L.C. Smith, Gerben J. C. Zwezerijnen, Marijke E. den Hollander, Josée M. Zijlstra, C. Willemien Menke-van der Houven van Oordt, Idris Bahce, Maqsood Yaqub, Ronald Boellaard","doi":"10.2967/jnumed.124.269272","DOIUrl":"https://doi.org/10.2967/jnumed.124.269272","url":null,"abstract":"<p>¹⁸F-FDG PET/CT imaging is widely used in oncology. Long–axial-field-of-view (LAFOV) PET/CT systems exhibit ultrahigh sensitivity and signal-to-noise ratios, enabling significant reductions in tracer activity and shorter acquisition times. This study aimed to evaluate the feasibility of using ultralow activities for semiquantitative measurements in ¹⁸F-FDG PET/CT imaging performed on an LAFOV PET/CT system through a high–low activity test–retest study. <strong>Methods:</strong> Eleven oncology patients underwent 2 ¹⁸F-FDG PET/CT scans, the first with standard activity (3.0 MBq/kg) and, within 7 d, 1 with ultralow activity (0.3 MBq/kg). List-mode data of both scans were resampled to simulate activities of 0.3 and 0.03 MBq/kg. Semiquantitative measurements (SUV_mean, SUV_peak, and SUV_max) and their repeatability in healthy organs and lesions were compared across different activities and reconstruction protocols. <strong>Results:</strong> SUV_mean remained stable across activity reductions and reconstruction protocols, whereas SUV_peak showed stability except when simulating 1% of the standard ¹⁸F-FDG activity. SUV_max significantly increased at lower ¹⁸F-FDG activities, particularly with clinically preferred scans. Repeatability analysis showed that SUV_mean and SUV_peak maintained variability within acceptable limits (&lt;15%) even at 0.03 MBq/kg, whereas SUV_max variability often exceeded these limits. Lesion detection was reliable at 0.3 MBq/kg, but several lesions could not be delineated at 0.03 MBq/kg, indicating compromised image quality. <strong>Conclusion:</strong> The use of ultralow ¹⁸F-FDG activity (0.3 MBq/kg) is feasible for PET/CT imaging on an LAFOV PET/CT system, as shown by semiquantitative measurements, repeatability analyses, lesion detectability, and semiautomated delineation methods. These findings support imaging protocols that keep radiation exposure levels as low as reasonably or practically achievable, which are particularly relevant for radiation-sensitive patients (e.g., children, pregnant women).</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 SNMMI Highlights Lecture: Cardiovascular Sciences","authors":"James T. Thackeray","doi":"10.2967/jnumed.125.269988","DOIUrl":"https://doi.org/10.2967/jnumed.125.269988","url":null,"abstract":"<p><em>The Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 y by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of summarizing selected significant presentations at the meeting were divided annually among 4 distinguished nuclear and molecular medicine subject matter experts. The 2024 Highlights Lectures were delivered on June 11 at the SNMMI Annual Meeting in Toronto, Canada. Presented here is the lecture by James T. Thackeray, PhD, Heisenberg Professor of Translational Cardiovascular Molecular Imaging, Hannover Medical School (Germany), who spoke on cardiovascular topics presented at the meeting. Note that in the following presentation summary, numerals in brackets represent abstract numbers as published in</em> The Journal of Nuclear Medicine <em>(2024;65[suppl 2])</em>.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy","authors":"Gunjan Kayal, Molly E. Roseland, Chang Wang, Kellen Fitzpatrick, David Mirando, Krithika Suresh, Ka Kit Wong, Yuni K. Dewaraja","doi":"10.2967/jnumed.124.269389","DOIUrl":"https://doi.org/10.2967/jnumed.124.269389","url":null,"abstract":"&lt;p&gt;We investigated pharmacokinetics, dosimetric patterns, and absorbed dose (AD)–effect correlations in [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) for metastatic neuroendocrine tumors (NETs) to develop strategies for future personalized dosimetry-guided treatments. &lt;strong&gt;Methods:&lt;/strong&gt; Patients treated with standard [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTATATE PRRT were recruited for serial SPECT/CT imaging. Kidneys were segmented on CT using a deep learning algorithm, and tumors were segmented at each cycle using a SPECT gradient-based tool, guided by radiologist-defined contours on baseline CT/MRI. Dosimetry was performed using an automated workflow that included contour intensity–based SPECT-SPECT registration, generation of Monte Carlo dose-rate maps, and dose-rate fitting. Lesion-level response at first follow-up was evaluated using both radiologic (RECIST and modified RECIST) and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-DOTATATE PET-based criteria. Kidney toxicity was evaluated based on the estimated glomerular filtration rate (eGFR) at 9 mo after PRRT. &lt;strong&gt;Results:&lt;/strong&gt; Dosimetry was performed after cycle 1 in 30 patients and after all cycles in 22 of 30 patients who completed SPECT/CT imaging after each cycle. Median cumulative tumor (&lt;em&gt;n&lt;/em&gt; = 78) AD was 2.2 Gy/GBq (range, 0.1–20.8 Gy/GBq), whereas median kidney AD was 0.44 Gy/GBq (range, 0.25–0.96 Gy/GBq). The tumor-to-kidney AD ratio decreased with each cycle (median, 6.4, 5.7, 4.7, and 3.9 for cycles 1–4) because of a decrease in tumor AD, while kidney AD remained relatively constant. Higher-grade (grade 2) and pancreatic NETs showed a significantly larger drop in AD with each cycle, as well as significantly lower AD and effective half-life (T&lt;sub&gt;eff&lt;/sub&gt;), than did low-grade (grade 1) and small intestinal NETs, respectively. T&lt;sub&gt;eff&lt;/sub&gt; remained relatively constant with each cycle for both tumors and kidneys. Kidney T&lt;sub&gt;eff&lt;/sub&gt; and AD were significantly higher in patients with low eGFR than in those with high eGFR. Tumor AD was not significantly associated with response measures. There was no nephrotoxicity higher than grade 2; however, a significant negative association was found in univariate analyses between eGFR at 9 mo and AD to the kidney, which improved in a multivariable model that also adjusted for baseline eGFR (cycle 1 AD, &lt;em&gt;P&lt;/em&gt; = 0.020, adjusted &lt;em&gt;R&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.57; cumulative AD, &lt;em&gt;P&lt;/em&gt; = 0.049, adjusted &lt;em&gt;R&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.65). The association between percentage change in eGFR and AD to the kidney was also significant in univariate analysis and after adjusting for baseline eGFR (cycle 1 AD, &lt;em&gt;P&lt;/em&gt; = 0.006, adjusted &lt;em&gt;R&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.21; cumulative AD, &lt;em&gt;P&lt;/em&gt; = 0.019, adjusted &lt;em&gt;R&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt; = 0.21). &lt;strong&gt;Conclusion:&lt;/strong&gt; The dosimetric behavior we report over different cycles and for different NET subgroups can be considered when optimizing PRRT to individual patients. The models we present ","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Experience with Dual-Time-Point [18F]Flurpiridaz PET/CT for Localization of Parathyroid Adenomas in Primary Hyperparathyroidism","authors":"Thorsten Derlin, Dennis Kleine-Döpke, Lavinia Neubert, Tobias L. Ross, Bastian P. Ringe, Moritz Schmelzle, Frank M. Bengel","doi":"10.2967/jnumed.124.269387","DOIUrl":"https://doi.org/10.2967/jnumed.124.269387","url":null,"abstract":"<p>We aimed to evaluate the feasibility of [¹⁸F]flurpiridaz PET/CT for localization of parathyroid adenomas in patients with primary hyperparathyroidism (pHPT). <strong>Methods:</strong> Data for 11 patients with pHPT undergoing dual-time-point [¹⁸F]flurpiridaz PET/CT for localization of hyperfunctioning parathyroid glands were retrospectively analyzed. PET/CT findings were compared with results of other imaging tests, laboratory parameters, intraoperative findings, and final histology, serving as the reference standard. <strong>Results:</strong> [¹⁸F]flurpiridaz PET/CT identified parathyroid adenomas in 10 (91%) of the 11 patients studied. Parathyroid adenomas were exclusively visualized in early PET images. Uptake in adenomas declined over time (SUV_max, −65% ± 17%; <em>P</em> = 0.002), as did uptake in background thyroid tissue (−56% ± 16%; <em>P</em> = 0.002). <strong>Conclusion:</strong> [¹⁸F]flurpiridaz PET images after administration had high detection efficacy in pHPT. This work provides a rationale for larger prospective studies to evaluate the use of [¹⁸F]flurpiridaz PET/CT for localization of hyperfunctioning parathyroid glands in comparison with other imaging tests.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}